pioglitazone has been researched along with Arteriosclerosis in 27 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes." | 9.10 | Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Baumstark, MW; Destani, R; Friedrich, I; Füllert, S; Konrad, T; Krebs, K; März, W; Wieland, H; Winkler, K, 2003) |
| " This study was undertaken to examine the in vivo effects of the thiazolidine compound pioglitazone (PIO) on carotid neointimal thickening, after endothelial injury in Wistar rats and vascular hypertrophy in stroke-prone spontaneously hypertensive rats (SHR-SP/Izm)." | 7.70 | Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. ( Demura, H; Irie, K; Muraki, T; Naruse, K; Naruse, M; Shizume, H; Tago, K; Tanabe, A; Tanaka, M; Yoshimoto, T; Zardi, L, 1999) |
| "Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects." | 6.71 | Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. ( Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I, 2005) |
| " In this study, we administered pioglitazone and pitavastatin for 16 weeks to 18 patients who had type 2 diabetes complicated by dyslipidemia and then investigated the influence of these 2 drugs on MDA-LDL(i." | 5.15 | [Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes]. ( Hayashi, S; Taguchi, A, 2011) |
| "The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA(1c) levels and increased plasma adiponectin concentrations relative to the control group (P < 0." | 5.10 | Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. ( Kono, S; Kuzuya, H; Nakao, K; Ogawa, Y; Satoh, N; Shimatsu, A; Sugawara, A; Sugiyama, H; Tagami, T; Uesugi, H; Usui, T; Yamada, K, 2003) |
| "The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes." | 5.10 | Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Baumstark, MW; Destani, R; Friedrich, I; Füllert, S; Konrad, T; Krebs, K; März, W; Wieland, H; Winkler, K, 2003) |
| "Pioglitazone improved insulin resistance and glycemic control, as well as Tg and HDL-C - which suggests that pioglitazone may reduce cardiovascular risk for patients with type 2 diabetes." | 5.09 | The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. ( Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S, 2001) |
| " Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis." | 4.82 | The metabolic basis of atherogenic dyslipidemia. ( Vinik, AI, 2005) |
| " This study was undertaken to examine the in vivo effects of the thiazolidine compound pioglitazone (PIO) on carotid neointimal thickening, after endothelial injury in Wistar rats and vascular hypertrophy in stroke-prone spontaneously hypertensive rats (SHR-SP/Izm)." | 3.70 | Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. ( Demura, H; Irie, K; Muraki, T; Naruse, K; Naruse, M; Shizume, H; Tago, K; Tanabe, A; Tanaka, M; Yoshimoto, T; Zardi, L, 1999) |
| "Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects." | 2.71 | Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. ( Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I, 2005) |
| "Type 2 diabetes is associated with increased cardiovascular risk." | 2.71 | Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. ( Forst, T; Konrad, T; Langenfeld, M; Lübben, G; Marx, N; Pfützner, A; Walcher, D, 2005) |
| "Pioglitazone (30 mg daily) was administered for 6 months in 53 patients." | 2.70 | Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. ( Koshiyama, H; Kuwamura, N; Minamikawa, J; Nakamura, Y; Shimono, D, 2001) |
| "Insulin resistance is now considered to be major pathogenesis for diabetic macroangiopathy." | 2.43 | [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin]. ( Daita, H; Mokuno, H; Tamura, H, 2006) |
| "Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors." | 2.42 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| "Treatment with pioglitazone decreased the neointimal content of lipid in 20-week-old mice from 50 +/- 6% to 30 +/- 7%, p=0." | 1.33 | Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E. ( Clough, MH; Schneider, DJ; Sobel, BE; Taatjes, DJ; Wadsworth, MP; White, MF, 2005) |
| "Because coronary artery disease is a major complication for such patients, it is important to determine the effects of PPARgamma activation on arteriosclerosis." | 1.31 | Antiinflammatory and antiarteriosclerotic effects of pioglitazone. ( Egashira, K; Hiasa, K; Ichiki, T; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Takeshita, A; Usui, M; Zhao, Q, 2002) |
| "Treatment with pioglitazone significantly improved glucose and lipid metabolism." | 1.30 | Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. ( Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 24 (88.89) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaku, K | 1 |
| Taguchi, A | 1 |
| Hayashi, S | 1 |
| Sugiyama, Y | 1 |
| Ishibashi, M | 1 |
| Egashira, K | 1 |
| Hiasa, K | 1 |
| Inoue, S | 1 |
| Ni, W | 1 |
| Zhao, Q | 1 |
| Usui, M | 1 |
| Kitamoto, S | 1 |
| Ichiki, T | 1 |
| Takeshita, A | 1 |
| Iida, KT | 1 |
| Kawakami, Y | 1 |
| Suzuki, M | 1 |
| Shimano, H | 1 |
| Toyoshima, H | 1 |
| Sone, H | 1 |
| Shimada, K | 1 |
| Iwama, Y | 1 |
| Watanabe, Y | 1 |
| Mokuno, H | 2 |
| Kamata, K | 1 |
| Yamada, N | 1 |
| Satoh, N | 1 |
| Ogawa, Y | 1 |
| Usui, T | 1 |
| Tagami, T | 1 |
| Kono, S | 1 |
| Uesugi, H | 1 |
| Sugiyama, H | 1 |
| Sugawara, A | 1 |
| Yamada, K | 1 |
| Shimatsu, A | 1 |
| Kuzuya, H | 1 |
| Nakao, K | 3 |
| Winkler, K | 1 |
| Konrad, T | 2 |
| Füllert, S | 1 |
| Friedrich, I | 1 |
| Destani, R | 1 |
| Baumstark, MW | 1 |
| Krebs, K | 1 |
| Wieland, H | 1 |
| März, W | 1 |
| Roberts, AW | 1 |
| Thomas, A | 1 |
| Rees, A | 1 |
| Evans, M | 1 |
| Tanaka, T | 2 |
| Fukunaga, Y | 2 |
| Itoh, H | 2 |
| Doi, K | 2 |
| Yamashita, J | 2 |
| Chun, TH | 2 |
| Inoue, M | 2 |
| Masatsugu, K | 2 |
| Saito, T | 2 |
| Sawada, N | 2 |
| Sakaguchi, S | 1 |
| Arai, H | 1 |
| Kobayashi, M | 1 |
| Watanabe, I | 1 |
| Tani, S | 1 |
| Anazawa, T | 1 |
| Kushiro, T | 1 |
| Kanmatsuse, K | 1 |
| Clough, MH | 1 |
| Schneider, DJ | 1 |
| Sobel, BE | 1 |
| White, MF | 1 |
| Wadsworth, MP | 1 |
| Taatjes, DJ | 1 |
| Pfützner, A | 1 |
| Marx, N | 2 |
| Lübben, G | 1 |
| Langenfeld, M | 1 |
| Walcher, D | 1 |
| Forst, T | 1 |
| Gaillard, V | 1 |
| Casellas, D | 1 |
| Seguin-Devaux, C | 1 |
| Schohn, H | 1 |
| Dauça, M | 1 |
| Atkinson, J | 1 |
| Lartaud, I | 1 |
| Vinik, AI | 1 |
| Tamura, H | 1 |
| Daita, H | 1 |
| Yoshimoto, T | 2 |
| Naruse, M | 2 |
| Nishikawa, M | 1 |
| Naruse, K | 2 |
| Tanabe, A | 2 |
| Seki, T | 1 |
| Imaki, T | 1 |
| Demura, R | 1 |
| Aikawa, E | 1 |
| Demura, H | 2 |
| Shizume, H | 1 |
| Tanaka, M | 1 |
| Tago, K | 1 |
| Irie, K | 1 |
| Muraki, T | 1 |
| Zardi, L | 1 |
| Koshiyama, H | 1 |
| Shimono, D | 1 |
| Kuwamura, N | 1 |
| Minamikawa, J | 1 |
| Nakamura, Y | 1 |
| Rosenblatt, S | 1 |
| Miskin, B | 1 |
| Glazer, NB | 1 |
| Prince, MJ | 1 |
| Robertson, KE | 1 |
| Hosoda, K | 1 |
| Kook, H | 1 |
| Ueda, M | 1 |
| Chiba, Y | 1 |
| Ogita, T | 1 |
| Ando, K | 1 |
| Fujita, T | 1 |
| Hsueh, WA | 1 |
| Law, RE | 1 |
| Kehrle, B | 1 |
| Kohlhammer, K | 1 |
| Grüb, M | 1 |
| Koenig, W | 1 |
| Hombach, V | 1 |
| Libby, P | 1 |
| Plutzky, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes[NCT01384058] | Phase 4 | 41 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for pioglitazone and Arteriosclerosis
| Article | Year |
|---|---|
[Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].
Topics: Animals; Arteriosclerosis; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2009 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2002 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten | 2003 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; D | 2005 |
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabeti | 2006 |
PPARgamma and atherosclerosis: effects on cell growth and movement.
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Sy | 2001 |
7 trials available for pioglitazone and Arteriosclerosis
| Article | Year |
|---|---|
[Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes].
Topics: Aged; Arteriosclerosis; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Ty | 2011 |
Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.
Topics: Adiponectin; Arteriosclerosis; Blood Pressure; Body Mass Index; C-Reactive Protein; Diabetes Mellitu | 2003 |
Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Topics: Arteriosclerosis; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; | 2003 |
Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide.
Topics: Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Sc | 2005 |
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
Topics: Acute-Phase Proteins; Aged; Arteriosclerosis; Biomarkers; Blood Coagulation Factors; Blood Glucose; | 2005 |
Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
Topics: Arteriosclerosis; Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Glycated Hemo | 2001 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Met | 2001 |
14 other studies available for pioglitazone and Arteriosclerosis
| Article | Year |
|---|---|
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans | 2002 |
[Early effect of therapy with pioglitazone. Vascular damage significantly reduced].
Topics: Arteriosclerosis; Carotid Stenosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic An | 2002 |
Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2002 |
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mell | 2003 |
[Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; H | 2003 |
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration.
Topics: Alitretinoin; Angioplasty, Balloon; Animals; Aorta; Arteriosclerosis; Binding, Competitive; Cell Lin | 2005 |
[Effect of pioglitazone, one of TZDs, on IGT-patients].
Topics: Adiponectin; Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gene Expression; | 2005 |
Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E.
Topics: Administration, Oral; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Hyperlipidemias; Hypoglyc | 2005 |
Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis.
Topics: Animals; Aorta; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Blood Pressure; Calcinosis; Cyto | 2005 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Dia | 1997 |
Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Bromodeoxyuridine; Carotid Arteries; Cell Division; DNA | 1999 |
Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Topics: Animals; Arteriosclerosis; Carotid Arteries; Cattle; Cell Division; Cells, Cultured; Chromans; Coron | 2001 |
PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.
Topics: Animals; Arteriosclerosis; Cattle; Cells, Cultured; Chromans; Drug Antagonism; Endothelium; Immunohi | 2001 |
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate | 2002 |